3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

Baselga, José; Segalla, Jgm; Roché, Henri; Giglio, A. Del; Ciruelos, Eva; Filho, Sebastião Cabral; Gómez, Patricia; Lluch, Ana; Llombart, A; Costa, Francisco

doi:10.1016/s1359-6349(09)72031-2

Cited by 23 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is planned to enroll 220 patients in each trial [30]. The first of these trials was recently reported at the ESMO/ECCO conference 2009 (European Society for Medical Oncology/ European Cancer Organisation) [13 ]. Patients receiving sorafenib and capecitabine had a significantly prolonged median PFS as compared with patients on capecitabine monotherapy (6.4 vs. 4.1 months, P ¼ 0.0006).…”

Section: Sorafenibmentioning

confidence: 99%

Angiogenesis inhibitors in the management of breast cancer

Bossung

Harbeck²

2010

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Novel antiangiogenic agents have produced positive data in clinical trials for breast cancer leading to the approval of bevacizumab for the first-line therapy of metastatic breast cancer. Other interesting substances such as multikinase inhibitors are currently being investigated. So far, angiogenesis inhibitors provide an additional therapeutic option for metastatic breast cancer; their role in early breast cancer as well as optimal patient selection will need further research.

show abstract

Section: Sorafenibmentioning

confidence: 99%

Angiogenesis inhibitors in the management of breast cancer

Bossung

Harbeck²

2010

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…In one randomized Phase IIb study including 229 patients with locally advanced breast cancer or MBC, patients were treated with sorafenib plus capecitabine versus capecitabine Novel targeted agents for the treatment of advanced breast cancer | Review www.future-science.com (SOLTI-0701) [98]. The combination arm resulted in an increase in median PFS; 6.4 versus 4.1 months (HR: 0.576; p = 0.0006).…”

Section: Sorafenibmentioning

confidence: 99%

Novel Targeted Agents for the Treatment of Advanced Breast Cancer

Vega¹,

Díaz-Cantón

Álvarez

2012

Future Med. Chem.

View full text Add to dashboard Cite

The discovery of the molecular processes involved in cancer development has led to the design of an array of targeted agents. These agents, directed to specific proteins in the machinery of cancer cells, interfere with vital cascades involved in cell invasion, metastasis, apoptosis, cell-cycle control and angiogenesis. In breast cancer, the main pathways studied and targeted by drugs are the HER2 pathway, EGFR, VEGF, PI3K/Akt/mammalian target of rapamycin (PI3K-M-Tor), IGF/IGFR, poly(ADP ribose) polymerase 1, HDAC and many others. In this review, we present the most promising studies of these new targeted therapies and novel combination of targeted therapies with cytotoxic agents for the treatment of breast cancer patients.

show abstract

“…Notably, the toxicities associated with combining sorafenib with chemotherapy can be substantial. For example, a phase II trial of sorafenib in combination with capecitabine demonstrated that the combination resulted in a higher incidence of grade 3 hand-foot syndrome than with capecitabine alone (45% versus 13%) [53]. Phase II trials of sorafenib in combination with other cytotoxic agents, including vinorelbine and ixabepilone, are ongoing.…”

Section: Sorafenibmentioning

confidence: 99%

Combining Emerging Agents in Advanced Breast Cancer

Luu

Chung

2011

The Oncologist

View full text Add to dashboard Cite

Newer treatments have improved survival for patients with metastatic breast cancer over the last two decades, and a battery of new cytotoxic and targeted therapies is continuing to enhance this trend. This review outlines recent data and ongoing research in this area, by highlighting new developments (regarding approved but relatively new classes of cytotoxic and targeted agents) and also new classes of targeted therapy that are undergoing clinical evaluation. Mechanisms for synergy between agents are discussed where data are available, as is information on the rationale behind the development of agents that inhibit angiogenesis, DNA repair, histone deacetylases, heat shock proteins, or various signaling pathways in tumor proliferation. The abundance of clinical research surrounding anticancer agents, together with ongoing cancer biology research, is expected to further increase the available pool of therapeutic options for metastatic breast cancer. Concomitantly, in the absence of an effective targeted monotherapy, a better understanding of the interplay between biologic and cytotoxic anticancer agents will improve our ability to rationally design combination regimens with better efficacy and tolerability. The Oncologist 2011;16:760 -771

show abstract

3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

Cited by 23 publications

References 0 publications

Angiogenesis inhibitors in the management of breast cancer

Angiogenesis inhibitors in the management of breast cancer

Novel Targeted Agents for the Treatment of Advanced Breast Cancer

Combining Emerging Agents in Advanced Breast Cancer

Contact Info

Product

Resources

About